The firm is focusing its resources on pipeline assets like IPH4502, an antibody-drug conjugate under development for treating Nectin-4-expressing cancers.

Signals from a Phase Ia trial of LP-184 in solid tumors suggested that patients with DNA damage response gene mutations might respond well to the drug.

The company has already been testing the autologous cell therapy, LioCyx-M004, in patients with certain liver cancers.